A Phase 2 interventional study of Brenipatide and Placebo in Major Depressive Disorder, sponsored by Eli Lilly and Company. Not yet recruiting at 75 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Depressive Disorder, Major by Eli Lilly and Company — 3 open to participants now, 3 under way, 2 of them phase 3. Depressive Disorder, Major · Eli Lilly and Company.
Among the 59 studies in Depressive Disorder, Major by Eli Lilly and Company, this one is the 25th largest by planned enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 2, and was the 59th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →3 of the 59 studies in Depressive Disorder, Major by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Brazil and 12 more countries
Ages 18–75
Eli Lilly and Company · Sites in United States, Australia, Brazil and 12 more countries
Ages 18–75
By country, each count listing its studies:
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 6 · Phase 3 22 · Phase 4 13
First in 2002; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 330 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 249 across the 55 interventional studies, 1,626 across the 1 observational. Of the 55 that completed or were terminated, 42 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 59 studies in Depressive Disorder, Major by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the safety and efficacy of brenipatide (LY3537031) as an add on therapy in participants with major depression who still have symptoms while taking a stable dose of standard of care anti-depressant medicine.
The study will last approximately 5 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Are reliable and willing to make themselves available for the duration of the study and attend required study visits, and are willing and able to follow study procedures as required, such as:
Exclusion Criteria:
Have a lifetime history or current diagnosis of the following:
Have type 1 diabetes mellitus, or a history of
Brenipatide administered subcutaneously (SC) + standard of care (SoC) anti-depressant
Drug: Brenipatide
Placebo administered SC + SoC anti-depressant
Drug: Placebo
Administered SC
Also known as: LY3537031
Administered SC
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS-9) Score
Time frame: Baseline, Week 10
Change from Baseline in Hamilton Depression Rating Scale Score
Time frame: Baseline, Week 10
Change from Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment Score
Time frame: Baseline, Week 10
Achievement of Body Weight Reduction ≥5% in Participants with a Baseline Body Mass Index (BMI) ≥25 kg/m²
Time frame: Baseline, Week 10
Number of Participants with Treatment-Emergent Anti-Drug Antibodies (ADA)
Time frame: Baseline, Up to Week 18
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2028, 18 months later.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's planned 18 months is close to that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brenipatide